The emergence of resistance against current antiretroviral drugs to human immunodeficiency virus type 1 (HIV-1) is an increasingly important concern to the continuous success of antiretroviral therapy to HIV-1-infected patients. In the past decade, a number of studies reported that the prevalence of transmitted drug resistance among newly diagnosed patients has reached an overall 9% prevalence worldwide. Also, a number of studies using longitudinal HIV-1 patient study cohorts demonstrated that the cellular HIV-1 DNA level in peripheral blood mononuclear cells (PBMCs) has a prognostic value for the progression of HIV-1 disease independently of plasma HIV-1 RNA load and CD4 count. Using a previously established molecular-beacon-based real-time PCR methodology, cellular HIV-1 DNA levels were quantified in newly diagnosed and antiretroviral-naive patients in Northern Greece recruited between 2009 and 2010 using a predefined enrolling strategy, in an effort to investigate whether there is any relationship between cellular HIV-1 DNA levels and HIV-1 transmitted drug resistance. As part of the same study, DNA sequences encoding the env (C2-C5 region of gp120) were also amplified from PBMC-extracted DNA in order to determine the genotypic coreceptor tropism and genetic subtype. Cellular HIV-1 DNA levels had a median of 3.309 log10 HIV-1 copies per 106 PBMCs and demonstrated no correlation between cellular HIV-1 DNA levels and HIV-1 transmitted drug resistance. An absence of association between cellular HIV-1 DNA levels with plasma viral HIV-1 RNA load and CD4 levels was also found reconfirming the previously published study. Genotypic analysis of coreceptor tropism indicated that 96% of samples, independently of the presence or not of genotypic drug resistance, were CCR5-tropic. Overall, the findings reconfirmed the previously proposed proposition that transmitted drug resistance does not have an impact on disease progression in HIV-1-infected individuals. Also, CCR5 coreceptor tropism dominance suggests that both drug-resistant and drug-sensitive strains behave similarly in early infection in newly diagnosed patients.
Get full access to this article
View all access options for this article.
References
1.
GulickRM, MellorsJW, HavlirD, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 1997; 337(11):734–739.
2.
HammerSM, SquiresKE, HughesMD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med, 1997; 337(11):725–733.
3.
HughesMD, JohnsonVA, HirschMS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med, 1997; 126(12):929–938.
4.
KatzensteinDA, HammerSM, HughesMD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med, 1996; 335(15):1091–1098.
5.
O'BrienWA, HartiganPM, MartinD, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med, 1996; 334(7):426–431.
6.
MellorsJW, RinaldoCRJr, GuptaP, WhiteRM, ToddJA, and KingsleyLA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 1996; 272(5265):1167–1170.
7.
DescampsD, ChaixML, AndreP, et al.: French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001–2002. J Acquir Immune Defic Syndr, 2005; 38(5):545–552.
8.
KozalMJ, AmicoKR, ChiarellaJ, et al.: Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS, 2004; 18(16):2185–2189.
9.
Leigh BrownAJ, FrostSD, MathewsWC, et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis, 2003; 187(4):683–686.
10.
VercauterenJ, WensingAM, van de VijverDA, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis, 2009; 200(10):1503–1508.
11.
WeinstockHS, ZaidiI, HeneineW, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis, 2004; 189(12):2174–2180.
12.
BartmeyerB, KuechererC, HouareauC, et al.: Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One, 2010; 5(10):e12718.
13.
BraccialeL, ColafigliM, ZazziM, et al.: Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors. J Antimicrob Chemother, 2009; 64(3):607–615.
14.
BurchellAN, BayoumiAM, RourkeSB, et al.: Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002–09. J Antimicrob Chemother, 2012; 67(11):2755–2765.
15.
CaneP, ChrystieI, DunnD, et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ, 2005; 331(7529):1368.
16.
JainV, LieglerT, VittinghoffE, et al.: Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. PLoS One, 2010; 5(12):e15510.
17.
KarlssonA, BjorkmanP, BrattG, et al.: Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003–2010. PLoS One, 2012; 7(3):e33484.
18.
KousiappaI, AchilleosC, HezkaJ, et al.: Molecular characterization of HIV type 1 strains from newly diagnosed patients in Cyprus (2007–2009) recovers multiple clades including unique recombinant strains and lack of transmitted drug resistance. AIDS Res Hum Retroviruses, 2011; 27(11):1183–1199.
19.
KousiappaI, van de VijverDA, DemetriadesI, and KostrikisLG: Genetic analysis of HIV type 1 strains from newly infected untreated patients in Cyprus: High genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses, 2009; 25(1):23–35.
20.
SkouraL, MetallidisS, BucktonAJ, et al.: Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece. J Antimicrob Chemother, 2011; 66(12):2831–2837.
21.
VercauterenJ, DerdelinckxI, SasseA, et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses, 2008; 24(3):355–362.
22.
ChunTW, JustementJS, MoirS, et al.: Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus. J Infect Dis, 2007; 195(12):1762–1764.
23.
FinziD, BlanksonJ, SilicianoJD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med, 1999; 5(5):512–517.
24.
FinziD, HermankovaM, PiersonT, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278(5341):1295–1300.
25.
SedaghatAR, SilicianoRF, and WilkeCO: Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis, 2008; 8:2.
26.
SilicianoJD, KajdasJ, FinziD, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med, 2003; 9(6):727–728.
27.
KostrikisLG, TouloumiG, KaranicolasR, et al.: Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol, 2002; 76(20):10099–10108.
28.
GoujardC, BonarekM, MeyerL, et al.: CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis, 2006; 42(5):709–715.
29.
KatzensteinTL, OliveriRS, BenfieldT, Eugen-OlsenJ, NielsenC, and GerstoftJ: Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly. Scand J Infect Dis, 2002; 34(7):529–533.
30.
MingaAK, AnglaretX, d'Aquin ToniT, et al.: HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr, 2008; 48(3):350–354.
31.
RouziouxC, HubertJB, BurgardM, et al.: Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis, 2005; 192(1):46–55.
32.
TierneyC, LatheyJL, ChristophersonC, et al.: Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis, 2003; 187(1):144–148.
33.
DemetriouVL, van de VijverDA, KousiappaI, et al.: Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe. PLoS One, 2010; 5(6):e10976.
34.
AntoniadouZA, KousiappaI, SkouraL, et al.: Molecular epidemiology of HIV-1 infection in northern Greece (2009–2010): Evidence of a transmission cluster of HIV-1 subtype A1 drug resistant strains among men having sex with men. AIDS Res Hum Retroviruses. 2013. [Epub ahead of print]; DOI:10.1089/aid.2013.0166.
35.
KostrikisLG, BagdadesE, CaoY, ZhangL, DimitriouD, and HoDD: Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: Identification of a new subtype designated subtype I. J Virol, 1995; 69(10):6122–6130.
36.
SingT, LowAJ, BeerenwinkelN, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther, 2007; 12(7):1097–1106.
37.
JensenMA, CoetzerM, van ‘t WoutAB, MorrisL, and MullinsJI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol, 2006; 80(10):4698–4704.
38.
JensenMA, LiFS, van't WoutAB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol, 2003; 77(24):13376–13388.
39.
TamuraK, PetersonD, PetersonN, StecherG, NeiM, and KumarS: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011; 28(10):2731–2739.
40.
GiffordRJ, de OliveiraT, RambautA, et al.: Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol, 2007; 81(23):13050–13056.
41.
TsiaraCG, NikolopoulosGK, BagosPG, et al.: Impact of HIV type 1 DNA levels on spontaneous disease progression: A meta-analysis. AIDS Res Hum Retroviruses, 2012; 28(4):366–373.
